$ cat ./records/backed-mrna-vaccine-platforms-for-tuberculosis-and-hiv-after-covi-2022.txt
Backed mRNA vaccine platforms for tuberculosis and HIV after COVID-19 proved the technology
[RECORD.TXT] · cat --full
After COVID-19 demonstrated that mRNA vaccines could be developed in under a year and manufactured at massive scale, the Gates Foundation accelerated investments to apply mRNA platforms to tuberculosis and HIV — two diseases that have resisted conventional vaccine approaches for decades. Gates argued that the same compressed development timelines and adaptable manufacturing that produced the COVID vaccines should now be directed at diseases killing 1.5 million and 600,000 people annually respectively. The Foundation funded multiple mRNA vaccine candidates in Phase 1 and Phase 2 trials by 2023.
Source: https://www.gatesfoundation.org/our-work/programs/global-health/vaccines
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Backed Rondo Energy — industrial heat battery storing renewable electricity as high-temperature heat
Next →
Backed marine cloud brightening research as a regionally targeted geoengineering approach
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.